Lawrence Livermore National Laboratory

Lab researchers aid COVID-19 response in antibody, anti-viral research

24-Mar-2020 2:40 PM EDT, by Lawrence Livermore National Laboratory

Newswise — Lawrence Livermore National Laboratory scientists are contributing to the global fight against COVID-19 by combining artificial intelligence/machine learning, bioinformatics and supercomputing to help discover candidates for new antibodies and pharmaceutical drugs to combat the disease.

Backed by five high performance computing (HPC) clusters and years of expertise in vaccine and countermeasure development, a COVID-19 response team of LLNL researchers from various disciplines has used modeling & simulation, along with machine learning, to identify about 20 initial, yet promising, antibody designs from a nearly infinite set of potentials and to examine millions of small molecules that could have anti-viral properties. The candidates will need to be synthesized and experimentally tested — which Lab researchers cautioned could take time — but progress is being made.

“For several decades, the Laboratory has been at the forefront of protecting the country against biological threats of any type,” said Lab Senior Science Adviser Dave Rakestraw, who formerly ran LLNL’s biodefense programs and is coordinating the Lab’s COVID-19 technical response. “We’ve been putting a large amount of focus for the last six years on applying  the computational resources at LLNL to try to accelerate the timescales for developing a response to an emerging biological threat. We’ve done that by using our extensive computational capabilities (staff and computer infrastructure) and developing partnerships with universities, drug companies and tech companies. That effort has put us in a position where we have tools now that are applicable to helping with the current response.”

When the COVID-19 outbreak began, LLNL’s Adam Zemla developed and published a predicted 3D protein structure of the virus, which was downloaded and used by more than a dozen outside research groups. Since then, the actual crystal structure of the key protein from SARS-CoV-2, the virus that causes COVID-19, has been determined, which closely matched the team’s predictions, researchers said.

Armed with the virus’ predicted 3D structure and a few antibodies known to bind and neutralize SARS, an LLNL team led by Daniel Faissol and Thomas Desautels used two HPC clusters to perform AI-driven virtual screening of antibodies capable of binding to SARS-CoV-2, generating high-fidelity simulations to test the molecular interactions for efficacy. The modeling platform, supported by the Defense Advanced Research Projects Agency (DARPA) and internal Laboratory Directed Research and Development (LDRD) funding, is the first of its kind in integrating experimental data, structural biology, bioinformatic modeling and molecular simulations – driven by a machine learning algorithm – to design antibody candidates. This platform was used to identify potential high value modifications to the SARS antibodies so that it binds to SARS-CoV-2.

“Our approach, while still being developed, is aimed at designing high quality antibody therapeutics or vaccines in extremely rapid time-scales for scenarios in which waiting for many rounds of time-consuming experimental steps is not an option,” said Faissol. “Experimental data and structural bioinformatics are important components to enable high-quality predictions, but integrating machine learning and molecular simulations on HPC are the key to enabling the speed and scalability we need to search and evaluate huge numbers of possible antibody designs.”

The approach has not only sped up the process considerably over selection guided solely by human intuition — narrowing down the number of antibody candidates from 1039 possibilities to a handful in a matter of weeks — but also has focused on areas where scientists may not have otherwise looked.

 “Now we’re not just searching blindly; we’re actually creating structures that we think are in the proper part of the design space, then we do our evaluations on those,” said Jim Brase, the Laboratory’s deputy associate director for Data Science. “We’ll get novelty, and — we hope — a higher percentage of real validated answers out of this approach at the end.”

Researchers said they are just beginning to look at the data and are currently working to arrange synthesis, as well as set up testing and evaluation  of the designs, through both internal efforts and targeted external collaborations..

Antiviral drug design

Another component of the multi-pronged response involves antiviral drug design. A group of Lab scientists led by Felice Lightstone and Jonathan Allen recently used dedicated access time on the entire Quartz supercomputing cluster to perform virtual screening of small molecules against two COVID-19 proteins. Using LLNL-customized software, created by Lab scientist Xiaohua Zhang, the LLNL team has performed a large-scale computational run to screen 26 million molecules against four protein sites (totaling more than 100 million docking calculations) to identify compounds that possibly could prevent infection or treat COVID-19. 

“Using the computational tools and data that we created from our American Heart Association’s Center for Accelerated Drug Discovery, we were able to computationally screen these molecules so quickly and at such a large scale,” Lightstone said. “This is the first step toward finding a new antiviral. We developed a whole pipeline for drug design and plan to continue in the coming weeks, ending with experimental testing of the predicted molecules.  This should speed up the drug design process.”

Some models being used to determine the molecules’ safety are derived from the system developed through the multi-institutional ATOM (Accelerating Therapeutics for Opportunities in Medicine) consortium, a project aimed at speeding up cancer drug discovery. That work has helped the Lab evaluate molecules in a timely manner and produce models useful for any outbreak, researchers said.

Need for DOE lab capabilities

LLNL scientists called the COVID-19 pandemic a “wake-up call” signifying the need for a longer-term investment and sustained government-wide effort, particularly in applying high performance computing to personalized medicine. 

“It has clarified the need for and value of leadership Department of Energy capabilities,” said Shankar Sundaram, director of LLNL’s Center for Bioengineering. “The Laboratory anticipated this kind of situation in pursuing a predictive biology initiative. The reason we were able to jump onto this quickly was not just because we had the capabilities, but because we’ve been thinking about these scenarios for a long time.”

LLNL is also adapting its portable, rapid PCR-based molecular diagnostics platform (Bio ID) developed by LLNL biomedical scientist Larry Dugan as a potential tool to quickly diagnose COVID-19.

The overall COVID-19 response effort involves all 17 DOE national laboratories. LLNL’s response team includes scientists and engineers from the Lab’ Center for Bioengineering, Forensic Science Center and Biodefense Knowledge Center (BKC), Biosciences and Biotechnology Division, and the HPC capabilities of cluster systems Quartz, Lassen, Corona, Pascal and Catalyst.




Filters close

Showing results

110 of 2448
Released: 2-Jul-2020 11:50 AM EDT
New Study Explains Potential Causes for “Happy Hypoxia” Condition in COVID-19 Patients
Loyola Medicine

A new research study provides possible explanations for COVID-19 patients who present with extremely low, otherwise life-threatening levels of oxygen, but no signs of dyspnea (difficulty breathing). This new understanding of the condition, known as silent hypoxemia or “happy hypoxia,” could prevent unnecessary intubation and ventilation in patients during the current and expected second wave of coronavirus.

Released: 2-Jul-2020 10:15 AM EDT
Stemming the Spread of Misinformation on Social Media
Association for Psychological Science

New research reported in the journal Psychological Science finds that priming people to think about accuracy could make them more discerning in what they subsequently share on social media.

29-Jun-2020 9:00 AM EDT
Coronavirus damages the endocrine system
Endocrine Society

People with endocrine disorders may see their condition worsen as a result of COVID-19, according to a new review published in the Journal of the Endocrine Society.

Released: 2-Jul-2020 8:50 AM EDT
Learn from the pandemic to prevent environmental catastrophe, scientists argue
University of Cambridge

• COVID-19 is comparable to climate and extinction emergencies, say scientists from the UK and US – all share features such as lagged impacts, feedback loops, and complex dynamics. • Delayed action in the pandemic cost lives and economic growth, just as it will with environmental crises – but on a scale “too grave to contemplate”.

Released: 1-Jul-2020 5:30 PM EDT
COVID-19 seed grants awarded to 7 ISU research projects
Iowa State University

Iowa State's COVID-19 Research Seed Grant program will support the initial stages of high-risk/high-reward projects that address the COVID-19 crisis.

Released: 1-Jul-2020 4:30 PM EDT
National Survey on COVID-19 Pandemic Shows Significant Mental Health Impact
Beth Israel Deaconess Medical Center

The findings of a nationwide survey assessing the effects of the COVID-19 pandemic on the emotional wellbeing of U.S. adults show 90 percent of survey respondents reported experiencing emotional distress related to the pandemic.

Released: 1-Jul-2020 2:40 PM EDT
Surveys Reveal Significant Shifts in Consumer Behavior During Pandemic
Rensselaer Polytechnic Institute (RPI)

The COVID-19 pandemic has significantly altered how people shop, how much they buy, the trips they take outside their homes, and the number of tele-activities — like work, medicine, and education — that have become commonplace. These changes were rapid and have tremendously impacted the economy, supply chains, and the environment. Two sets of surveys were conducted by researchers at Rensselaer Polytechnic Institute in an effort to quantify and understand these unprecedented shifts — and evaluate the likelihood they may last after the pandemic has ended.

Released: 1-Jul-2020 2:20 PM EDT
COVID-19 Fatality Risk Is Double Earlier Estimates: Study
Columbia University, Mailman School of Public Health

In one of the most robust studies of COVID-19 mortality risk in the United States, researchers estimate an infection fatality rate more than double estimates from other countries, with the greatest risk to older adults. Columbia University Mailman School of Public Health scientists and New York City Department of Health and Mental Hygiene colleagues published the findings on the pre-print server medRxiv ahead of peer review.

Released: 1-Jul-2020 2:15 PM EDT
Study Examines Limiting School Capacity for New York City Reopening
Columbia University, Mailman School of Public Health

Data modeling projections by Columbia University Mailman School of Public Health scientists evaluate potential policies to reduce new infections, hospitalizations, and deaths in coming months, including by limiting school capacity by 50 percent or capping capacity of certain industries to 25 percent during Phase Four, as well as by implementing an “adaptive PAUSE” system to re-implement social distancing rules during a rebound. The researchers have been working with the New York City Department of Health and Mental Hygiene on COVID-19 planning. Their new report is posted on Github.


Showing results

110 of 2448

close
0.8157